Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS

Oxidative stress and neurodegeneration: the involvement of iron

(2018) Alessia Carocci et al.   BIOMETALS

Disease-Modifying Treatment in Progressive Multiple Sclerosis

(2018) John Robert Ciotti et al.   Current Treatment Options in Neurology

Age and immunity: What is “immunosenescence”?

(2018) Graham Pawelec   EXPERIMENTAL GERONTOLOGY

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis

(2018) Robert Zivadinov et al.   RADIOLOGY

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

(2018) Mathias Granqvist et al.   JAMA Neurology

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

(2018) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

(2017) Dennis Chan et al.   LANCET NEUROLOGY

Poster Session 1

(2017)   Multiple Sclerosis Journal

Clinical trial design for progressive MS trials

(2017) Matteo Pardini et al.   Multiple Sclerosis Journal

Clinical outcome measures for progressive MS trials

(2017) Daniel Ontaneda et al.   Multiple Sclerosis Journal

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poster Session 1

(2017)   Multiple Sclerosis Journal

Clinical trial design for progressive MS trials

(2017) Matteo Pardini et al.   Multiple Sclerosis Journal

Clinical outcome measures for progressive MS trials

(2017) Daniel Ontaneda et al.   Multiple Sclerosis Journal

High dose biotin as treatment for progressive multiple sclerosis

(2017) Gary Birnbaum et al.   Multiple Sclerosis and Related Disorders

B cells and antibodies in progressive multiple sclerosis: Contribution to neurodegeneration and progression

(2016) Judith Fraussen et al.   AUTOIMMUNITY REVIEWS

Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation

(2016) Tatiana Koudriavtseva et al.   Frontiers in Human Neuroscience

The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures

(2016) Catherine O’Sullivan et al.   Journal of Neuroinflammation

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Aging and multiple sclerosis

(2016) Shaik Ahmed Sanai et al.   Multiple Sclerosis Journal

Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

(2016) Frédéric Sedel et al.   NEUROPHARMACOLOGY

Laquinimod in the treatment of multiple sclerosis: a review of the data so far

(2016) Jan Thöne et al.   Drug Design Development and Therapy

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Aging and multiple sclerosis

(2016) Shaik Ahmed Sanai et al.   Multiple Sclerosis Journal

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment

(2016) Peter Kosa et al.   Frontiers in Neurology

Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study

(2015) Shiv Saidha et al.   ANNALS OF NEUROLOGY

Progressive multiple sclerosis

(2015) Daniel Ontaneda et al.   CURRENT OPINION IN NEUROLOGY

Fingolimod induces neuroprotective factors in human astrocytes

(2015) Franziska S. Hoffmann et al.   Journal of Neuroinflammation

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

High doses of biotin in chronic progressive multiple sclerosis: A pilot study

(2015) Frédéric Sedel et al.   Multiple Sclerosis and Related Disorders

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

(2015) Karen Ann Ribbons et al.   PLoS One

Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis

(2014) Renaud A. Du Pasquier et al.   CNS DRUGS

The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis

(2014) J. Van Schependom et al.   EUROPEAN JOURNAL OF NEUROLOGY

Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future

(2014) Itay Raphael et al.   Expert Review of Clinical Immunology

Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

(2014) Cecilie Jacobsen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease

(2014) Olga Voevodskaya et al.   Frontiers in Aging Neuroscience

Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?

(2014) Jae Young Lee et al.   Acta Neuropathologica Communications

The Statin–Iron Nexus: Anti-Inflammatory Intervention for Arterial Disease Prevention

(2013) Leo R. Zacharski et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Fingolimod phosphate promotes the neuroprotective effects of microglia

(2013) Hiromi Noda et al.   JOURNAL OF NEUROIMMUNOLOGY

Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions

(2013) Veela Mehta et al.   PLoS One

Slower immune system aging in women versus men in the Japanese population

(2013) Katsuiku Hirokawa et al.   Immunity & Ageing

How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?

(2013) Franz Fazekas et al.   Frontiers in Neurology

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

(2012) Jack Antel et al.   ACTA NEUROPATHOLOGICA

Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs

(2012) Jason G. Cyster et al.   Annual Review of Immunology

Cortical lesion load associates with progression of disability in multiple sclerosis

(2012) M. Calabrese et al.   BRAIN

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis

(2012) M. Tutuncu et al.   Multiple Sclerosis Journal

Might the beneficial effects of statin drugs be related to their action on iron metabolism?

(2012) L. Mascitelli et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

(2011) Per Soelberg Sorensen et al.   LANCET NEUROLOGY

Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis

(2011) Nancy L. Monson et al.   PLoS One

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

(2010) M. Axelsson et al.   JOURNAL OF NEUROLOGY

The natural history of secondary progressive multiple sclerosis

(2010) M. Koch et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Longitudinal changes in cortical thickness associated with normal aging

(2010) Madhav Thambisetty et al.   NEUROIMAGE

Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?

(2010) F. Barkhof et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

(2009) P Rolan et al.   EXPERT OPINION ON PHARMACOTHERAPY

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

(2008) Howard L. Weiner   JOURNAL OF NEUROLOGY

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS

(2008) J. J. Kragt et al.   NEUROLOGY